Endo To Submit Response To FDA On Lidoderm Bioequivalence Recommendation
This article was originally published in The Pink Sheet Daily
Executive Summary
Endo argues bioequivalence of the lidocaine patch should be demonstrated through clinical efficacy study, not pharmacokinetic data.
You may also be interested in...
Clinical Trials Not Required For Lidoderm Generics, FDA Tells Endo
The agency distinguishes the lidocaine pain patch from topical dermatological drugs intended to treat skin diseases in rejecting Endo’s call that ANDA sponsors demonstrate bioequivalence through clinical trials, rather than merely pharmacokinetic studies.
Endo’s Lidoderm Marketing Practices Under HHS OIG Investigation
Subpoena asks for documents relating to off-label promotion of pain patch.
Endo’s Lidoderm Marketing Practices Under HHS OIG Investigation
Subpoena asks for documents relating to off-label promotion of pain patch.